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Warfarin skin necrosis (WSN) is an infrequent complication of warfarin treatment
and is characterized by painful ulcerative skin lesions that appear a few days after
the start of warfarin treatment. Calciphylaxis also appears as painful skin lesions
caused by tissue injury resulting from localized ischemia caused by calciﬁcation of
small- to medium-sized vessels in patients with end-stage renal disease. We report
on a patient who presented with painful skin ulcers on the lower extremities after
the administration of warfarin after a valve operation. Calciphylaxis was considered
ﬁrst because of the host factors; eventually, the skin lesions were diagnosed as WSN
by biopsy. The skin lesions improved after warfarin discontinuation and short-term
steroid therapy. Most patients with end-stage renal disease have some form of
cardiovascular disease and some require temporary or continual warfarin treatment.
It is important to differentiate between WSN and calciphylaxis in patients with
painful skin lesions.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Warfarin skin necrosis (WSN) is a nonhemorrhagic compli-
cation of warfarin treatment, and its prevalence is reported to
be only 0.01e0.1% among patients taking warfarin [1]. Calci-
phylaxis is a rare, challenging complication of end-stage renal
disease (ESRD) with a high mortality rate. WSN and calciphy-
laxis have common clinical features, and warfarin treatment is
a representative risk factor for calciphylaxis [2]. We describe aicine, Samsung Medical
Medicine, 81 Irwon-ro,
JE Lee).
ty of Nephrology. Published b
/4.0/).patient undergoing peritoneal dialysis who exhibited painful
ulcerative skin lesions after warfarin administration.Case report
A 52-year-old man with aortic stenosis was admitted to the
thoracic surgery department. He had undergone kidney
transplantation 15 years previously but had been on peritoneal
dialysis for the past 2 years because of graft failure. He was also
diagnosed with secondary hyperparathyroidism accompanied
bymetastatic pulmonary calciﬁcation and had received ethanol
injection to a right parathyroid nodule.
On hospital day (HD) 7, he underwent surgery to replace the
aortic valve with a titanium-based prosthesis. During the
operation, his aorta showed severe wall calciﬁcation. The ﬁnal
pathology ﬁnding of the original aortic valve was ﬁbrocalciﬁcy Elsevier. This is an open access article under the CC BY-NC-ND license
Figure 2. Chest radiography. Calciﬁed consolidation is shown in both
upper lung ﬁelds.
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to his medication lists without heparin overlapping. On HD 18,
hemorrhagic pustules developed suddenly on both feet. The
skin lesions were distributed over both feet and were accom-
panied by xerotic scale (Fig. 1). The lesions were tender. At that
time, there was no change in his condition other than the skin
lesions.
The patient's medications included renalmin (vitamin B and
C complex), sevelamer, cinacalcet, and divalproex, all of which
he had been taking before admission, and famotidine, atenolol,
risperidone, isosorbide-5-mononitrate, Mypol (ibuprofen/co-
deine/acetaminophen complex), and warfarin, all of which
were added after the surgery. During the hospitalization, serial
assessment showed that C-reactive protein concentration was
increasing, and intravenous vancomycin was added on HD 19.
The initial differential diagnosis of the skin lesions was drug
eruption and metastatic infection, and a skin biopsy and
microbiology examination were performed. While waiting for
the result, the skin lesions changed to necrotic ulcers accom-
panied by substantial pain and progressed to the thigh level of
both legs.
The patient was referred to the nephrology department
because of painful skin lesions on HD 21. At that time, labora-
tory data showed a serum calcium of 8.7 mg/dL, phosphorus of
2.2 mg/dL, and intact parathyroid hormone level of 155.4
(reference range, 11.0e62.0) pg/mL. Chest radiographies
showed extensive calciﬁed consolidation in both upper lung
ﬁelds (Fig. 2). We considered the possibility of calciphylaxis
because his lungs and blood vessels showed extensive calciﬁ-
cation and the host factors such as ESRD, secondary hyper-
parathyroidism, and recent warfarin commencement
suggested the possibility of calciphylaxis. On HD 23, the pa-
thology report indicated ﬁbrinoid necrosis of entire dermal
vessels, epidermal necrosis, and vesicles (Fig. 3A). Of note, no
vascular calciﬁcationwas detectable (Fig. 3B). Further review of
the patient revealed no evidence of systemic vasculitis, and
tests for antineutrophil cytoplasmic antibodies (antiproteinase
3 and antimyeloperoxidase) were negative.
On HD 27, we decided to withhold warfarin after consider-
ation ofWSNand started parenteral steroid (methylprednisoloneFigure 1. Skin lesions on both feet. On HD 19, 11 days after the start of
warfarin, erythematous pustules with tenderness developed suddenly on
the lower aspects of both feet. The skin lesions expanded to the thigh level
over the next few days.
HD, hospital day.40 mg every 8 hours) after discussion with the allergy
department. On HD 29, he was transferred to his local tertiary
hospital for personal reasons. In that hospital, steroid therapy
was continued and then tapered without the use of
anticoagulants.
Twelve days after discharge, the patient visited our hospital
because of epistaxis and was readmitted. At that time, the skin
lesions had improved, and the steroid was tapered out. On HD 4
of the second hospitalization, we tried again to give the patient
warfarin with enoxaparin. From HD 9 of the second hospitali-
zation, painful skin lesions became aggravated. The reemergence
of the painful skin lesions was strong evidence of WSN, and we
immediately stopped the warfarin treatment and used short-
term systemic steroid. The skin lesions and pain disappeared.
We ﬁnally diagnosed the skin lesions as WSN, and enoxaparin
was used as the anticoagulant. He was discharged after the
systemic steroid was stopped and given enoxaparin as the
maintenance anticoagulant.
Discussion
WSN is an infrequent nonhemorrhagic complication of
warfarin treatment. The ﬁrst case was described in 1943, and
the prevalence is reported to be 0.01e0.1% [1]. In Korea, 2 cases
have been reported. One involved a 70-year-old man who
presented with hemorrhagic bulla and ecchymosis on the right
upper extremity that appeared after 6 days of warfarin treat-
ment for acute stroke. He had no history of medical illness
except hypertension [3]. The other case involved a 48-year-old
woman who presented with skin necrosis on both breasts
about 3 weeks after double valve replacement surgery and
warfarin treatment. She also had no other signiﬁcant medical
history [4]. There are no reports of WSN in patients with ESRD.
In patients with ESRD, WSN may be more challenging because
of the need for an important differential diagnosis from calci-
phylaxis. When a patient with ESRD presents with painful skin
lesions after warfarin treatment, the clinician should consider
the possibility of the 2 main differential diagnosesdWSN
versus calciphylaxis.
Although the pathogenesis is not fully understood, WSN re-
sults from the pharmacologic effects of warfarin. During the
early phase of treatment, warfarin creates a paradoxically
transient hypercoagulable state because several of the
Figure 3. Pathologic ﬁndings of the skin. (A) Microscopic examination revealed intraepidermal vesicles (arrows) and multifocal necrosis of keratinocytes
(arrowheads) with mixed inﬂammatory cell inﬁltration. Superﬁcial dermis also shows diffuse inﬁltration of neutrophils, lymphocytes, and some eosinophils
(hematoxylin and eosin, 100). (B) Most of the small- and medium-sized dermal vessels showed extensive ﬁbrinoid necrosis (arrows) and mixed in-
ﬂammatory cell inﬁltration in the vascular wall and perivascular area. Calciﬁcation was not identiﬁed throughout the dermal vessels included in the
specimen (hematoxylin and eosin, 400).
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have different half-lives. By contrast, calciphylaxis is a tissue
injury caused by local ischemia resulting from metastatic
calciﬁcation of vessels. Despite the different etiologies, the
clinical manifestations of these distinct disease entities are
similar, and it can be difﬁcult to differentiate thembased onlyon
the clinical presentation. Both conditions can manifest initially
as relativelymild skin lesions resembling an erythematous rash
or livedo reticularis and then progress to skin ulcers or necrosis
[1,5]. Pain commonly accompanies the skin lesions. The skin
lesions caused by WSN occur on the extremities, breasts, but-
tocks, and thighs, and the lesions caused by calciphylaxis occur
on body areas with abundant adipose tissue [1,6].
When treating this patient, some clinical ﬁndings made us
consider both WSN and calciphylaxis. The patient exhibited
painful skin lesions after warfarin administration, and these
lesions progressed to necrotic ulcers. The patient's other con-
ditions, such as ESRD, hyperparathyroidism, and history of
metastatic calciﬁcation, led us to consider the diagnosis of
calciphylaxis, for which warfarin is also a risk factor. Although
the most painful sites were both thighs whenwe examined the
patient on HD 24, the initial skin lesions were localized to the
feet, which is not a typical location, and were accompanied by
hemorrhagic pustules and xerotic scale, which we thought
somewhat atypical.
We obtained deﬁnite clues from the histology ﬁndings. The
main histopathology ﬁndings of WSN are diffuse microthrombi
and ﬁbrin deposits within the dermal and subcutaneous cap-
illaries, venules, and deep veins, accompanied by endothelial
cell damage [7]. By contrast, the typical ﬁndings of calciphylaxis
are the presence of medial calciﬁcation and intimal prolifera-
tion of small- to medium-sized arteries, primarily in dermal
and subcutaneous tissues [8]. In one review of a series of 16
patients with calciphylaxis, all the skin biopsy specimens
showed small-vessel calciﬁcation regardless of the disease
stage [5].
It is still controversial whether warfarin can be reintroduced
safely in patients with WSN. A few literature have suggested
that warfarin can be reattempted in combination with heparin
and with a gradual (1 by 1 mg) increase of the warfarin dose
[1,9,10]. It could also be applied for the preventive strategy for
WSN. In particular, in patients with limited indication for lower
molecular weight heparin or novel oral anticoagulant drugsuch as ESRD, reintroduction of warfarin rather than switch to
other anticoagulant could be acceptable. However, reintro-
duction of warfarin aggravated the skin lesions despite the
minimum dose of warfarin given with low-molecular-weight
heparin in this patient. Considering the relatively rapid
improvement after steroid use, we believe that hypersensitivity
might contribute at least partly to the development of skin
lesions.
It is important to differentiate between WSN and calciphy-
laxis because the medical management differs between these
conditions [6]. The most important management of WSN is
interruption of warfarin treatment and treatment with heparin,
vitamin K, and protein C concentrate. When treating calciphy-
laxis, it is important to control calciumephosphate meta-
bolism, especially by stopping the use of calcium-based
binders. Parathyroidectomy, sodium thiosulfate administration,
and hyperbaric oxygen therapy are also options. The purpose of
treatment is to avoid secondary skin infections, and adequate
wound care and sometimes antibiotics are required. Both
conditions may require surgical debridement if medical man-
agement fails.
This ESRD patient exhibited painful skin lesions after
warfarin treatment commencement and had risk factors for
calciphylaxis. We initially suspected calciphylaxis but diag-
nosed WSN based on the results of the skin biopsy. The skin
lesions improved with discontinuation of warfarin and short-
term use of systemic steroid. It is important for nephrologists
to be aware of these 2 conditions and to quickly differentiate
WSN from calciphylaxis to provide proper management of the
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